Shire LLC

Synthonics Incorporated

New River Pharmaceuticals Inc.

University of Virginia Patent Foundation

Other

Insmed Pharmaceuticals, Inc.

Thomas Piccariello

Travis C Mickle

James Scott Moncrief

Suma Krishnan

Christopher Lauderback

Barney Bishop

Robert A Oberlender

Bernhard J Paul

Christopher Verbicky

John D Price

Michaela E Mulhare

Scott B Palmer

Mary C Spencer

Randal Kirk

Rob Oberlender

Lawrence Peter Olon

Nancy Johnston Boerth

Joel M Linden

Christal Mickle

Joseph Larner

Laura Huang

John Price

Alex Saunders Goldstein

Randal J Kirk

Randall J Kirk

Anne F LeClercq

George Vandenhoff

Gamini Samanaryke

Christopher A Verbicky

Lawrence P Olon

The invention relates to supramolecular metal coordinated liothyronine (triiodothyronine, T3) compositions, methods of preparing such compositions, methods of purifying and formulating supramolecular metal coordinated liothyronine, and methods of treating hypothyroidism and other disease states using such compositions.

Metallo-liothyronine

Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.

Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients

A coordination complex having a physiologically acceptable pKincludes a metal and a biologically active agent. The pKof the coordination complex is less than the pKof the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients

Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties.

Frequency modulated drug delivery (FMDD)

The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

Active agent delivery systems and methods for protecting and administering active agents

A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.

Metal coordinated compositions

The invention provides a 'street-safe' version of a controlled substance that permits the therapeutically beneficial effects of the substance while reducing or eliminating the euphoric effects that lead to substance abuse. The invention provides pharmaceutical compositions comprising a controlled substance and a carbohydrate covalently bound to said controlled substance in a manner that renders said controlled substance pharmacologically inactive or substantially diminishes its activity and methods of using the same.

Carbohydrate conjugates to prevent abuse of controlled substances

The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Abuse-resistant amphetamine prodrugs

Growing community of inventors

Blacksburg, VA, United States of America

Thomas Piccariello